Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

NCT03641313 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03641313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03641313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 16, 2020
Completion date
January 28, 2027
Enrollment
17 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, unresectable gastric adenocarcinoma, unresectable gastroesophageal junction adenocarcinoma